Cargando…
Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature
Lenalidomide is indicated in the front-line management of multiple myeloma. More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676979/ https://www.ncbi.nlm.nih.gov/pubmed/33274089 http://dx.doi.org/10.1155/2020/8825618 |